Question 1

What is a cash flow statement?

Accepted Answer

A cash flow statement tracks the actual cash moving in and out of a company during a period. It's divided into three sections: operating activities (core business), investing activities (assets and investments), and financing activities (debt and equity). Unlike the income statement, it shows real cash rather than accounting profits.

Question 2

What is operating cash flow?

Accepted Answer

Operating cash flow is the cash generated from a company's core business operations. It adjusts net income for non-cash items like depreciation and changes in working capital. Strong operating cash flow indicates the business can fund operations without external financing.

Question 3

What is free cash flow (FCF)?

Accepted Answer

Free cash flow is operating cash flow minus capital expenditures. It represents the cash available for dividends, share buybacks, debt repayment, or reinvestment. FCF is considered one of the most important metrics for evaluating a company's financial health.

Question 4

What are capital expenditures?

Accepted Answer

Capital expenditures (CapEx) are funds spent on acquiring or maintaining physical assets like property, equipment, and technology. CapEx appears in the investing activities section and is subtracted from operating cash flow to calculate free cash flow.

Question 5

How is RNAZ's cash generation trending?

Accepted Answer

Review TransCode Therapeutics's operating cash flow and free cash flow figures in the quarterly and annual data above. Consistent growth in operating cash flow relative to net income indicates high-quality earnings.

Breakdown	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2021	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 2025	Dec 2024	Mar 2024	Dec 2023	Dec 2022	Mar 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Operating Activities
Net Income	-34.66	-16.75	-18.55	-18.55	-17.57	-6.84	-6.84	-2.34	-0.61	-0.45
Depreciation & Amortization	0.11	0.53	0.52	0.52	0.10	0.04	0.04	0.00	0.00	0.00
Deferred Income Tax	0.00	0.00	0.00	0.00	0.00	0.88	0.00	0.00	0.00	0.00
Stock Based Compensation	0.49	1.70	1.04	1.04	0.40	0.19	0.19	0.05	0.00	0.02
Change in Working Capital	0.02	-0.35	-1.08	-1.08	1.31	0.43	0.47	0.31	0.00	0.02
Change in Accounts Receivable	-0.95	0.00	0.36	0.00	-0.36	0.00	0.00	0.00	0.00	0.00
Change in Accounts Payable	0.00	0.00	0.00	-1.30	1.84	2.29	2.29	0.19	-0.05	0.00
Change in Other Working Capital	5.25	-0.35	-1.44	-1.08	1.31	-1.85	0.00	0.12	0.05	0.02
Other Operating Activities	5.25	1.54	0.00	0.00	0.00	0.04	0.00	1.50	0.10	0.11
Net Cash from Operating Activities	-19.52	-13.34	-18.07	-18.07	-15.76	-5.27	-5.27	-0.49	-0.51	-0.30
Investing Activities
Capital Expenditures	-0.01	-0.02	-0.04	-0.04	-0.10	-0.25	-0.25	0.00	0.00	0.00
Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Cash from Investing Activities	0.00	-0.02	-0.04	-0.04	-0.10	-0.25	-0.25	0.00	0.00	0.00
Financing Activities
Debt Repayment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.19	0.50	0.55
Common Stock Issued	8.85	16.40	15.91	15.91	0.01	26.34	26.34	0.00	0.00	0.00
Other Financing Activities	22.67	0.00	0.00	0.00	0.00	-0.82	-0.85	-0.07	0.00	-0.04
Net Cash from Financing Activities	31.52	16.40	15.91	15.91	0.01	25.52	25.52	1.12	0.50	0.51
Summary
Net Change in Cash	12.00	3.04	-2.20	-2.20	-15.86	20.00	20.00	0.62	-0.01	0.21
Cash at Beginning of Period	5.81	2.77	4.97	4.97	20.83	0.83	0.83	0.20	0.21	0.00
Cash at End of Period	17.81	5.81	2.77	2.77	4.97	20.83	20.83	0.83	0.20	0.21
Free Cash Flow	-19.52	-13.36	-18.11	-18.11	-15.86	-5.52	-5.52	-0.49	-0.51	-0.30
Supplemental Disclosures
Interest Paid	0.00	0.02	0.00	0.03	0.04	0.00	0.02	0.00	0.00	0.00

TransCode Therapeutics (RNAZ) Cash Flow Statement

TransCode Therapeutics Cash Flow Statement Analysis

Frequently Asked Questions About TransCode Therapeutics Cash Flow

Free Cash Flow (FCF)

FCF Per Share

Cash Flow to Debt

Dividend Payout Ratio

EBITDA

Return on Invested Capital (ROIC)